US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal infection for use in people aged 10 through 25 years, the company said on ...
pharmaphorum3d
GSK trails after Pfizer in 5-in-1 meningococcal vaccine race
The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...
FiercePharma26d
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
The shot mixes the antigenic components of GSK’s established meningococcal vaccines Bexsero and Menveo, which target MenB and MenACWY, respectively, to offer broader coverage in fewer doses.
HealthDay on MSN15d
FDA Approves More Broadly Protective Meningococcal Vaccine
The US FDA has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease.
Nature2y
Meningococcal group A, C, Y and W-135 conjugate vaccine
In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis ...
pharmaphorum6d
GSK chases down Pfizer in 5-in-1 meningitis jab contest
That hasn’t stopped Bexsero’s steady growth, with sales approaching the $1 billion threshold last year, while Menveo added another $430 million. Pfizer has been something of an also-ran in the ...